-$0.03 EPS Expected for Aurora Cannabis Inc (NYSE:ACB) This Quarter

Brokerages expect Aurora Cannabis Inc (NYSE:ACB) to announce ($0.03) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Aurora Cannabis’ earnings. The lowest EPS estimate is ($0.05) and the highest is ($0.01). Aurora Cannabis reported earnings per share of $0.09 in the same quarter last year, which suggests a negative year over year growth rate of 133.3%. The company is expected to report its next quarterly earnings report on Monday, November 11th.

According to Zacks, analysts expect that Aurora Cannabis will report full year earnings of ($0.10) per share for the current fiscal year, with EPS estimates ranging from ($0.16) to ($0.02). For the next year, analysts forecast that the company will report earnings of ($0.02) per share, with EPS estimates ranging from ($0.15) to $0.05. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Aurora Cannabis.

A number of brokerages recently commented on ACB. Stifel Nicolaus reissued a “sell” rating and issued a $5.00 price objective (down from $7.00) on shares of Aurora Cannabis in a research note on Thursday, September 12th. Bank of America cut shares of Aurora Cannabis from a “buy” rating to a “neutral” rating and set a $7.30 price objective on the stock. in a research note on Thursday, July 18th. Pi Financial set a $7.00 price objective on shares of Aurora Cannabis and gave the company a “buy” rating in a research note on Tuesday, October 15th. ValuEngine raised shares of Aurora Cannabis from a “hold” rating to a “buy” rating in a research note on Wednesday, August 21st. Finally, MKM Partners cut shares of Aurora Cannabis to a “sell” rating in a research note on Friday, September 20th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.84.

NYSE ACB traded up $0.01 during trading hours on Monday, reaching $3.69. The company’s stock had a trading volume of 14,682,249 shares, compared to its average volume of 19,920,086. The stock has a market cap of $3.80 billion, a PE ratio of -16.77 and a beta of 2.39. Aurora Cannabis has a fifty-two week low of $3.40 and a fifty-two week high of $10.32. The company’s 50-day moving average is $4.79 and its two-hundred day moving average is $6.89. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.14 and a current ratio of 1.52.

Large investors have recently added to or reduced their stakes in the business. Mackey Komara & Dankovich LLC purchased a new position in Aurora Cannabis in the 2nd quarter valued at about $27,000. Executive Wealth Management LLC lifted its holdings in Aurora Cannabis by 102.1% in the 2nd quarter. Executive Wealth Management LLC now owns 3,900 shares of the company’s stock valued at $30,000 after purchasing an additional 1,970 shares in the last quarter. Kistler Tiffany Companies LLC lifted its holdings in shares of Aurora Cannabis by 77.9% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 4,075 shares of the company’s stock worth $32,000 after acquiring an additional 1,785 shares during the period. Resources Investment Advisors LLC. lifted its holdings in shares of Aurora Cannabis by 825.7% during the 2nd quarter. Resources Investment Advisors LLC. now owns 4,962 shares of the company’s stock worth $39,000 after acquiring an additional 4,426 shares during the period. Finally, Manchester Financial Inc. purchased a new position in shares of Aurora Cannabis during the 2nd quarter worth about $43,000. Institutional investors own 8.80% of the company’s stock.

Aurora Cannabis Company Profile

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Featured Story: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on Aurora Cannabis (ACB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.